Literature DB >> 35381600

The Relationship between Fatigue and a Clinically Accessible Measure of Switching in Individuals with Multiple Sclerosis.

Fareshte Erani1, Joshua McKeever1,2, John D Medaglia1,3, Maria T Schultheis1.   

Abstract

OBJECTIVE: We examined whether fatigue in multiple sclerosis (MS) is linked to switching processes when switching is measured by the Trail Making Test (TMT).
METHOD: Eighty-three participants with MS were administered a battery of standardized tests of switching, working memory, and processing speed. Ordinary least squares regression models were used to estimate the association between fatigue severity and switching above and beyond attention, working memory, and processing speed.
RESULTS: We found a negative association between TMT performance and fatigue severity score. When measures of processing speed and working memory were included in the model, the switching measure continued to uniquely contribute to fatigue severity.
CONCLUSIONS: There may be a unique relationship between fatigue and switching processes identifiable by clinical measures of switching. Future research should continue to investigate this relationship by using both behavioral and neural markers to test models of fatigue to eventually identify specific intervention targets.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Assessment; Executive functions; Multiple sclerosis

Mesh:

Year:  2022        PMID: 35381600      PMCID: PMC9396450          DOI: 10.1093/arclin/acac017

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   3.448


  23 in total

Review 1.  Fatigue and basal ganglia.

Authors:  A Chaudhuri; P O Behan
Journal:  J Neurol Sci       Date:  2000-10-01       Impact factor: 3.181

2.  Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities.

Authors:  I Sánchez-Cubillo; J A Periáñez; D Adrover-Roig; J M Rodríguez-Sánchez; M Ríos-Lago; J Tirapu; F Barceló
Journal:  J Int Neuropsychol Soc       Date:  2009-05       Impact factor: 2.892

Review 3.  Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy.

Authors:  Benzi M Kluger; Lauren B Krupp; Roger M Enoka
Journal:  Neurology       Date:  2013-01-22       Impact factor: 9.910

Review 4.  Is there a cognitive signature for MS-related fatigue?

Authors:  Katrin Hanken; Paul Eling; Helmut Hildebrandt
Journal:  Mult Scler       Date:  2014-09-25       Impact factor: 6.312

Review 5.  Multiple sclerosis-associated fatigue.

Authors:  Lauren B Krupp; Dana J Serafin; Christopher Christodoulou
Journal:  Expert Rev Neurother       Date:  2010-09       Impact factor: 4.618

6.  An examination of four models predicting fatigue in multiple sclerosis.

Authors:  Lauren B Strober; Peter A Arnett
Journal:  Arch Clin Neuropsychol       Date:  2005-07       Impact factor: 2.813

7.  Mental fatigue and task control: planning and preparation.

Authors:  M M Lorist; M Klein; S Nieuwenhuis; R De Jong; G Mulder; T F Meijman
Journal:  Psychophysiology       Date:  2000-09       Impact factor: 4.016

8.  Evaluating neuropsychological impairment in chronic fatigue syndrome.

Authors:  J H Vercoulen; E Bazelmans; C M Swanink; J M Galama; J F Fennis; J W van der Meer; G Bleijenberg
Journal:  J Clin Exp Neuropsychol       Date:  1998-04       Impact factor: 2.475

9.  Cognitive function as measured by trail making test in patients with COPD.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  West J Nurs Res       Date:  2014-04-14       Impact factor: 1.967

10.  Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.

Authors:  Bardia Nourbakhsh; Nisha Revirajan; Bridget Morris; Christian Cordano; Jennifer Creasman; Michael Manguinao; Kristen Krysko; Alice Rutatangwa; Caroline Auvray; Salman Aljarallah; Chengshi Jin; Ellen Mowry; Charles McCulloch; Emmanuelle Waubant
Journal:  Lancet Neurol       Date:  2020-11-23       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.